Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CGON

CG Oncology

CGON Lead: NDA Submitted 8 Biotech Distilled articles ↓ 22 filings & releases ↓ Cash $28.2M (Sep 30, 2026) ↓ 8 verdicts ↓ 1 timing quote ↓
Oncology Gene Therapy

Market cap $6.79B 89.3M shares (10-Q, Nov 4, 2026) × $75.99 close Nov 6, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Creto BLA filing2026Creto BLA filing, 2026, notable
  2. cretostimogene BLA HR filing4Q 2026cretostimogene BLA HR filing, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Capital (as filed)

Cash
$28.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$956M Sep 30, 2026
Operating cash flow
−$47.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.03B cash, runway 2029 per the update of Aug 6, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on CG Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-23 Buy core CG Oncology (CGON): Scientific Deep Dive for Creto and Pipeline Products Best-in-class Phase 3 data (75.5% CR), clean safety profile, resolved legal overhang, and fortress balance sheet make CGON a high-conviction buy with M&A appeal.
  2. 2026-02-28 Buy core UPDATE: CG Oncology (CGON) - EoY Update Balance sheet upgraded to near-$1B fortress after aggressive ATM execution, eliminating financing overhang while clinical thesis remains pristine ahead of PIVOT-006 readout.
  3. 2026-05-09 Buy core UPDATE: CG Oncology (CGON) — Q1 2026 Status Check ATM fully drawn at $57.56 average closes dilution chapter; two near-term catalysts (AUA May 16 combo data, PIVOT-006 topline) with BLA on defined Q4 2026 path maintain high-conviction buy.
  4. 2026-05-16 Buy core UPDATE: CG Oncology (CGON) — The Gem Combo Clears the Bar CORE-008 Cohort CX posted 85.7% ITT / 92.3% efficacy-evaluable CR with 0% Grade 3+ TRAEs, validating the Force Multiplier combination platform; PIVOT-006 remains the next and bigger catalyst.
  5. 2026-05-26 Buy core UPDATE: CG Oncology (CGON) — The COO Walks, the CEO Doubles Up COO departure adds launch-readiness execution risk but does not change the clinical platform or balance sheet; 7.5% drawdown into clean combo data may be an attractive entry for those accepting near-term execution risk.
  6. 2026-08-07 Buy core UPDATE: CG Oncology (CGON) — The ATM Reloads at $72 ANI post-trial motions denied and BOND-003 peer-reviewed in Lancet Oncology de-risk the asset for M&A; new $500M ATM at $72 is dilutive but executed from strength; PIVOT-006 randomized readout remains the key unresolved risk.
  7. 2026-10-13 Buy core UPDATE: CG Oncology (CGON) - The Commercial Chair Is Filled CCO vacancy filled by Isabel Kalofonos, a multi-launch specialist oncology executive, closing the launch-readiness gap opened by the COO's June exit while clinical platform and legal picture remain unchanged.
  8. 2026-11-07 Buy core UPDATE: CG Oncology (CGON) - The Readout Gets a Month PIVOT-006 topline pinned to November 2026 with 12-month combo durability data in December; balance sheet better than modeled; ANI appeal live but low-odds; randomized readout is the binary event the thesis was built to be tested by.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)